New combo therapy shows promise for young cancer patients who relapsed
NCT ID NCT03445858
First seen Jan 25, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This early-phase study tested a combination of three treatments—pembrolizumab, decitabine, and targeted radiation—in 22 children and young adults (ages 1 to 40) with relapsed or refractory solid tumors or lymphoma. The main goals were to see if the combination is safe and tolerable, and to get an early look at whether it can shrink tumors. The study is complete, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Conditions
Explore the condition pages connected to this study.